TABLE 5.
Neutralization and fusion inhibition antibody titers
| Titer type | Antibody titer for study group administered:
|
||||
|---|---|---|---|---|---|
| SB 20973 at dose of:
|
Placebo (n = 10) | ||||
| 10 mg/kg (n = 11) | 5 mg/kg (n = 11) | 1.25 mg/kg (n = 9) | 0.25 mg/kg (n = 7) | ||
| Neutralization titer | |||||
| Mean (SD) | |||||
| Predose | 155 (66) | 228 (89) | 704 (338) | 278 (119) | 1,255 (984) |
| Day 6 postdose | 286 (89) | 375 (102) | 508 (185) | 304 (127) | 1,146 (985) |
| Median (range) | |||||
| Predose | 67 (2–675) | 109 (2–877) | 234 (2–3,098) | 234 (2–855) | 129 (2–10,000) |
| Day 6 postdose | 131 (32–961) | 242 (32–1,130) | 310 (59–1,890) | 132 (11–770) | 104 (2–10,000) |
| Fusion titer | |||||
| Mean (SD) | |||||
| Predose | 11 (4) | 22 (13) | 35 (19) | 52 (25) | 26 (15) |
| Day 6 postdose | 36 (9) | 96 (41) | 76 (33) | 72 (33) | 12 (5) |
| Median (range) | |||||
| Predose | 2 (2–37) | 2 (2–137) | 18 (2–179) | 48 (2–189) | 16 (2–160) |
| Day 6 postdose | 34 (2–86) | 52 (2–467) | 45 (2–268) | 39 (2–233) | 2 (2–42) |